Nektar Doses First Patient In NKTR-102 Phase 1 Study
Nektar said that the study is being conducted at University Hospitals Case Medical Center of the Case Comprehensive Cancer Center in Cleveland, Ohio. NKTR-102 is a novel topoisomerase
Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and machine learning (ML).
MSD and Adcock Ingram intend to co-promote and distribute products from various therapeutic areas including: asthma, dermatology, hypercholesterolemia, hypertension, migraine and osteoporosis as well as a portfolio of
Wolters Kluwer Health said that its ProVation MD software for procedure documentation and coding compliance replaces dictation/transcription and streamlines the coding and billing process. Wolters Kluwer Health claimed
miRagen is planning to develop and commercialise single-stranded LNA-based product candidates intended for the treatment of cardiovascular disease by utilizing Santaris Pharma proprietary Locked Nucleic Acid (LNA) Drug